Tran William T, Ibáñez Carolina, Pinto Mauricio P, Sanchez Cesar, Czarnota Gregory J, Merino Tomas
Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto ON M4N 3M5, Canada.
Departamento de Hemato-Oncologia, Pontificia Universidad Catolica de Chile, Santiago 8330032, Chile.
Ecancermedicalscience. 2020 Jan 23;14:1006. doi: 10.3332/ecancer.2020.1006. eCollection 2020.
Radiation recall (RR) is a fairly uncommon and unpredictable phenomenon caused by an acute inflammatory reaction in a previously irradiated area. Several antineoplastic drugs have been previously associated with RR reactions including anthracyclines and taxanes like docetaxel, paclitaxel or antimetabolites.
Here we report for the first time a case of a recall reaction to Eribulin mesylate, a novel chemotherapeutic compound that affects microtubule polymerisation, approved for the treatment of metastatic or locally advanced breast cancers (BCs). We present the case of a 61-year-old female BC patient originally diagnosed with bilateral BC with metastatic disease that went through several lines of chemotherapy and radiation therapy (RT); RR reaction was observed following Eribulin treatment and sequential palliative RT.
This case report raises awareness about these fairly rare phenomena when prescribing Eribulin, or any new chemotherapeutic after RT to prevent and treat as early as possible to avoid further patient complications.
放射回忆（RR）是一种相当罕见且不可预测的现象，由先前受照射区域的急性炎症反应引起。先前已有多种抗肿瘤药物与RR反应相关，包括蒽环类药物以及多西他赛、紫杉醇等紫杉烷类药物或抗代谢药物。
在此，我们首次报告一例对甲磺酸艾瑞布林的回忆反应病例。甲磺酸艾瑞布林是一种影响微管聚合的新型化疗化合物，已被批准用于治疗转移性或局部晚期乳腺癌（BC）。我们介绍了一名61岁的女性BC患者，最初诊断为双侧BC伴转移性疾病，接受了多线化疗和放射治疗（RT）；在艾瑞布林治疗及随后的姑息性RT后观察到RR反应。
本病例报告提高了在开具艾瑞布林或放疗后使用任何新的化疗药物时对这些相当罕见现象的认识，以便尽早预防和治疗，避免患者出现进一步并发症。
